[Allergic conjunctival disorders].
Ebihara
Nobuyuki
N
Department of Ophthalmology, Juntendo University School of Medicine.
D018926:Anti-Allergic Agents / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000938:Antigen-Presenting Cells / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D015550:Cell Degranulation; D018925:Chemokines / Q000502:physiology; D003233:Conjunctivitis, Allergic / Q000145:classification / Q000188:drug therapy / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism / Q000502:physiology; D004359:Drug Therapy, Combination; D047093:Eosinophil Major Basic Protein / Q000502:physiology; D047209:Eosinophil Peroxidase / Q000502:physiology; D004804:Eosinophils / Q000276:immunology; D005109:Extracellular Matrix / Q000502:physiology; D006634:Histamine H1 Antagonists / Q000008:administration & dosage; D006636:Histamine Release; D006801:Humans; D007073:Immunoglobulin E; D008407:Mast Cells / Q000378:metabolism / Q000502:physiology; D009883:Ophthalmic Solutions; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D018925:Chemokines; D016207:Cytokines; D006634:Histamine H1 Antagonists; D009883:Ophthalmic Solutions; D007073:Immunoglobulin E; D047209:Eosinophil Peroxidase; D047093:Eosinophil Major Basic Protein